Portal de Periódicos da CAPES

Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA

1999; Wiley; Volume: 38; Issue: S2 Linguagem: Inglês

10.1046/j.1365-4362.1999.00012.x

1365-4632

Aditya K. Gupta, Julien Lambert,

Cutaneous lymphoproliferative disorders research

International Journal of DermatologyVolume 38, Issue S2 p. 53-64 Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA Aditya K. Gupta MD, FRCP. (C), Aditya K. Gupta MD, FRCP. (C) From The Division of Dermatology, Department of Medicine, Sunnybrook and Women’s College Health Sciences Center (Sunnybrook site), University of Toronto, Toronto, Ontario, Canada and Department of Dermatology, University Hospital of Antwerp, BelgiumSearch for more papers by this authorJulien Lambert MD, PhD, Julien Lambert MD, PhD From The Division of Dermatology, Department of Medicine, Sunnybrook and Women’s College Health Sciences Center (Sunnybrook site), University of Toronto, Toronto, Ontario, Canada and Department of Dermatology, University Hospital of Antwerp, BelgiumSearch for more papers by this author Aditya K. Gupta MD, FRCP. (C), Aditya K. Gupta MD, FRCP. (C) From The Division of Dermatology, Department of Medicine, Sunnybrook and Women’s College Health Sciences Center (Sunnybrook site), University of Toronto, Toronto, Ontario, Canada and Department of Dermatology, University Hospital of Antwerp, BelgiumSearch for more papers by this authorJulien Lambert MD, PhD, Julien Lambert MD, PhD From The Division of Dermatology, Department of Medicine, Sunnybrook and Women’s College Health Sciences Center (Sunnybrook site), University of Toronto, Toronto, Ontario, Canada and Department of Dermatology, University Hospital of Antwerp, BelgiumSearch for more papers by this author First published: 25 December 2001 https://doi.org/10.1046/j.1365-4362.1999.00012.xCitations: 16 Aditya K. Gupta, MD, frcp ( c)Suite 6490 Wonderland Road SouthLondonOntarioCanada N6K 1L6E-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Gupta, AK, Jain, HC, Lynde, CW et al. Prevalence of unsuspected onychomycosis in patients visiting dermatologists’ offices in Ontario, Canada: a multicenter study of 2001 patients. Int J Dermatol 1997; 36, 783 787. 2 Charif, M & Elewski, BE. The prevalence of onychomycosis in Northeastern Ohio. Arch Dermatol 1997; 133, 1172 1173. 3 Gupta, AK, Sauder, DN, Shear, NH. Antifungal agents: an overview. Part 1 J Am Acad Dermatol 1994; 30, 677 700. 4 Gupta, AK & Shear, NH. An update, with a risk–benefit evaluation of the newer oral antifungal agents used to treat onychomycosis. Drug Safety 1999; in press. 5 Gupta, AK & Shear, NH. The new oral antifungal agents for onychomycosis of the toenails. J Eur Acad Dermatol Venerol 1999; in press. 6 Gupta, AK. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis. Pharmacoeconomics 1998; 13, 243 256. 7 Epstein, E. How often does oral treatment of toenails onychomycosis produce a disease-free nail? Arch Dermatol 1998; 134, 1551 1554. 8 Arenas, R, Fernandez, G, Dominguez, L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. Int J Dermatol 1991; 30, 586 589. 9 Baran, R, Belaich, S, Beylot, C et al. Comparative multicenter double-blind study of terbinafine (250 mg per day) versus griseofulvin (1 g per day) in the treatment of dermatophyte onychomycosis. J Dermatol Treat 1997; 8, 93 97. 10 Faergemann, J, Anderson, C, Hersle, K et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32, 750 753. 11 Hofmann, J, Bräutigam, M, Weidinger, G et al. Treatment of toenail onychomycosis: a randomized, double-blind study with terbinafine and griseofulvin. Arch Dermatol 1995; 131, 919 922. 12 Walsøe, I, Stangerup, M, Svejgaard, E. Itraconazole in onychomycosis: open and double-blind studies. Acta Derm Venereol (Stockh.) 1990; 70, 137 140. 13 Arenas, R, Dominguez-Cherit, J, Fernández, LM. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1993; 34, 138 143. 14 Bräutigam, M, Nolting, S, Schopf, RE et al. Randomized double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Br Med J 1995; 311, 919 922. 15 De Backer, M, De Keyser, P, De Vroey, C et al. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs. itraconazole 200 mg/day-a double-blind comparative trial. Br J Dermatol 1996; 134 (Suppl. 46), 16 17. 16 Degreef, H, Del Palacio, A, Mygind, S et al. Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Derm Venerol (Stockh) 1999; 79, 221 223. 17 Elewski, BE, Scher, RK, Aly, R et al. Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. Cutis 1997; 59, 217 220. 18 Haneke, E, Delescluse, J, Plinck, E et al. The use of itraconazole in onychomycosis. Eur J Dermatol 1996; 6, 7 10. 19 Havu, V, Brandt, H, Heikkilä, H et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol 1997; 136, 230 234. 20 Honeyman, JF, Talarico, FS, Arruda, LHF et al. Itracanazole versus terbinafine (LAMISIL®): which is better for the treatment of onychomycosis? J Eur Acad Dermatol Venereol 1997; 9, 215 221. 21 Jones, HE & Zaias, N. Double-blind, randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. Int J Dermatol 1996; 35, 589 590. 22 Odom, R, Daniel, R, Aly, R. A double blind randomized comparison of itraconazole capsules and placebo in the treatment of onychomycosis of the toenail. J Am Acad Dermatol 1996; 35, 110 111. 23 Itraconazole product monograph. Titusville (NJ). Janssen Pharmaceutica Inc, 1996. 24 Bonifaz, A, Carrasco-Gerard, E, Saúl, A. Itraconazole in onychomycosis: intermittent dose schedule. Int J Dermatol 1997; 36, 70 72. 25 Itraconazole package insert (Canada). Toronto. Janssen Pharmaceutica Inc., 1997. 26 Evans, EGV, Sigurgeirsson, B, The, L.I. ON study group. Double-blind randomized study of continuous terbinafine compared with intermittent itraconazole in the treatment of toenail onychomycosis. Br J Med 1999; 318, 1031 1035. 27 Ginter, G & De Doncker, P. An intermittent 1-week dosing regimen for the treatment of toenail onychomycosis in dermatological patients. Mycoses 1998; 41, 235 238. 28 Haneke, E, Abeck, D, Ring, J. The safety and efficacy of intermittent therapy with itraconazole for finger- and toenail onychomcyosis: a multicenter trial. Zeitschriftfuer Hautkrankheiten 1997; 10, 737 740. 29 Haneke, E, Tajerbashi, M, De Doncker, P et al. Itraconazole in the treatment of onychomycosis: a double-blind comparison with miconazole. Dermatology 1998; 196, 323 329. 30 Kejda, J. Itraconazole pulse therapy vs. terbinafine continuous dosing for toenail onychomycosis. Postgrad Med. (Suppl.) ;, 19994 Ein press . 31 Negroni, R, Arechvala, A, Bonvehi, P. Treatment of onychomycosis due to mycelial fungi. Revista Argentina de Micologia 1998; 21, 8 14. 32 Svejgaard, E et al. In ( P De Doncker J Van Custem G Piérard et al. eds). Itraconazole compared to terbinafine in superficial fungal infections: from petri dish to patient! Poster P206. Presented at The Fifty-sixth Annual American Academy of Dermatology Meeting, Orlando, Florida, USA, February 27–March 4 1998. 33 Tosti, A, Piraccini, BM, Stinchi, C et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34, 595 600. 34 Wang, DL, Wang, AP, Li, RY, Wang, R. Therapeutic efficacy and safety of 1-week intermittent therapy with itraconazole for onychomycosis in a Chinese patient population. Dermatology 1999; 99, 47 49. 35 Alpsoy, E, Yilmaz, E, Basaran, E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol1996. 36 De Backer, M, De Keyser, P, Massart, DL et al. Terbinafine (Lamisil®) 250 mg/day and 500 mg/day are equally effective in a 16 week oral treatment of toenail onychomycosis. A double-blind multicentre trial . In: ( RJ. Hay eds). International Perspective on Lamisil® (Series: CCT Healthcare Congress and Symposium, No 101). London: CCT Healthcare Communications Ltd.,, 1994: pp 39 43. 37 Goodfield, MJD, Andrew, L, Evans, EGV. Short term treatment of dermatophyte onychomycosis with terbinafine. Br Med J 1992; 304, 1151 1154. 38 Havu, V, Heikkila, AH, Kuokkanen, K et al. A study to compare the efficacy of Lamisil® (terbinafine) and Diflucan® (fluconazole) in patients with onychomycosis Poster 132. J Eur Acad Dermatol Venereol 1996; 7 (Suppl. 2), S154. 39 Svejgaard, EL, Brandrup, F, Kragballe, K et al. Oral terbinafine in toenail dermatophytosis. Acta Derm Venereol (Stockh.) 1997; 77, 66 69. 40 Taush, I, Bräutigam, M, Weidinger, G, Jones, TC. and the Lagos V study group. Evaluation of 6 weeks’ treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks’ therapy. Br J Dermatol 1997; 136, 737 742. 41 Terbinafine package insert (United States). East Hanover, NJ. Novartis Pharmaceuticals Corporation, 1996. 42 Van Der Schroeff, JG, Cirkel, PKS, Crijns, MB et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992; 126, 36 39. 43 Watson, A, Marley, J, Ellis, D, Williams, T. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol 1995; 33, 775 779. 44 Fräki, J, Heikkilä, H, Kero, M et al. An open-label, non-comparative, multicenter evaluation of fluconazole with or without urea nail pedicure for treatment of onychomycosis. Cur Ther Res 1997; 58, 481 491. 45 Montero-Gei, F, Robles-Soto, ME, Schlager, H. Fluconazole in the treatment of severe onychomycosis. Int J Dermatol 1996; 35, 587 588. 46 Scher, RK, Breman, D, Rich, P et al. A placebo-controlled, randomized, double-blind trial of once-weekly fluconazole (150 mg, 300 mg, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998; 38, S77 S86. 47 Goldfarb, NJ & Sulzberger, MB. Experiences in one hundred thirty-seven patients with oral griseofulvin. Arch Dermatol 1960; 81, 859 862. 48 Kaminsky, A. Comparative effects of griseofulvin on onychomycosis and on psoriais. Arch Dermatol 1960; 60, 838 840. 49 Williams, DI. Griseofulvin and Trichophyton rubrum infections. Arch Dermatol 1960; 81, 769 771. 50 Davies, RR, Everall, JD, Hamilton, E. Mycological and clinical evaluation of griseofulvin for chronic onychomycosis. Br Med J 1967; 3, 464 469. 51 Korting, HC, Schafer-Korting, M, Zienicke, H et al. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother 1993; 37, 2064 2068. 52 Russell, B, Frain-Bell, W, Riddell, RW et al. Chronic ringworm infection of the skin and nails treated with griseofulvin. Lancet.; I. 1140 1147., 1960. 53 Hay, RJ, Clayton, YM, Griffiths, WAD et al. A comparative double-blind study of ketoconazole and griseofulvin in dermatopohytosis. Br J Dermatol 1985; 112, 691 696. 54 Piepponen, T, Blomqvist, K, Brandt, H et al. Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. J Antimicrob Chemother 1992; 29, 195 205. 55 Stevenson, CJ & Djavahizwili, N. Chronic ringworm of the nails. Lancet.; I. 373 374., 1961. 56 Levin, H, Alden, HS, Ajello, L. Use of griseofulvin in office practice. Arch Dermatol 1960; 81, 827 832. 57 Quintaville, P. Onychomycosis treated with ultrafine griseofulvin. J Am Podiat Assoc 1966; 56, 119 120. 58 Dillaha, CJ & Jansen, GT. Dosage requirements of griseofulvin in onychomycosis due to Trichophyton rubrum. Arch Dermatol 1960; 81, 192 198. 59 Blank, H, Smith, GJ, Roth, FJ et al. Griseofulvin for the systemic treatment of dermatomycoses. JAMA 1959; 171, 2168 2174. 60 Maibach, HI & Klingman Am. Short-term treatment of onychomycosis with griseofulvin. Arch Dermatol 1960; 18, 733 734. 61 González-Ochoa, A & Ahumada-Padilla, M. New schemes in the treatment of dermatophhytoses with griseofulvin. Arch Dermatol 1960; 81, 833 837. 62 Haneke, E, Tausch, I, Bräutigam, M et al. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995; 32, 72 77. 63 Hargreaves, GK. The treatment of onychomycosis with griseofulvin. Br J Dermatol 1960; 72, 358 364. 64 André, J, De Doncker, P, Laporet, M et al. Onychomycosis caused by Microsporum canis: treatment with itraconazole. J Am Acad Dermatol 1995; 32, 1052 1053. 65 Hanifin, JM & Tofte, SJ. Itraconazole therapy for recalcitrant dermatophyte infections. J Am Acad Dermatol 1988; 18, 71. 66 Rongioletti, F, Robert, E, Tripodi, S et al. Treatment of onychomycosis with itraconazole. J Dermatol Treat 1992; 2, 145 146. 67 Stary, A, Storch, M, Hörting-Müller, I. Systemic treatment of onychomycosis with itraconazole: clinical and mycological results (Abstract). 3rd Congress of the European Academy of Dermatology and Venereology;. September 26–30; Copenhagen.: 348, 1993. 68 Hay, RJ, Clayton, YM, Moore, MK et al. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol 1988; 119, 359 366. 69 DePadova-Elder, SM, Ditre, CM, Kantor, GR et al. Candidiasis endocrinopathy syndrome. Arch Dermatol 1994; 130, 19 22. 70 Kim, JA, Ahn, KJ, Kim, JM et al. Efficacy and tolerability of itraconazole in patients with fingernail onychomycosis: a 6-week pilot study. Curr Ther Res 1995; 56, 1066 1075. 71 De Doncker, PRG, Scher, RK, Baran, RL et al. Itraconazole therapy is effective for pedal onychomycosis caused by some non-dermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 35 patients. J Am Acad Dermatol 1997; 36, 173 177. 72 Hay, RJ, Baran, R, Moore, MK et al. Candida onychomycosis: an evaluation of the role of Candida species in nail disease. Br J Dermatol 1988; 118, 47 58. 73 Krishbaum, BA. Itraconazole therapy for onychomycosis: case reports. Cutis 1996; 58, 371 374. 74 Tosti, A, Piraccini, BM, Vinczi, C et al. Itraconazole in the treatment of two young brothers with chronic mucocutaneous candidiasis. Ped Dermatol 1997; 14, 146 148. 75 Willemsen, M, De Doncker, P, Willems, J et al. Posttreatment itraconazole levels in the nail. J Am Acad Dermatol 1992; 26, 731 735. 76 De Doncker, P, Van Lint, J, Dockx, P et al. Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis. Cutis 1995; 56, 180 183. 77 De Doncker, P, Decroix, J, Pierard, GE et al. Itraconazole pulse therapy is effective in the treatment of onychomycosis: a pharmacokinetic/pharmacodynamic and clinical evaluation. Arch Dermatol 1996; 132, 34 41. 78 Wu, J, Wen, H, Liao, W. Small-dose itraconazole pulse therapy in the treatment of onychomycosis. Mycoses 1997; 40, 397 400. 79 Ramos -e, -Silva, M, Marques, SA, Gontijo, B et al. Efficacy and safety of itraconazole pulse therapy: Brazilian multicentric study on toenail onychomycosis caused by dermatophytes. J Eur Acad Dermatol Venereol 1998; 11, 109 116. 80 Luyton, C, André, J, Walraevens, C, De Doncker, P. Yellow nail syndrome and onychomycosis. Dermatology 1996; 192, 406 408. 81 Elewski, BE. Trichophyton rubrum onychomycosis in a 17-year-old girl. Cutis 1997; 60, 253 254. 82 Odom, RB, Aly, R, Scher, RK et al. A multicenter, placebo-controlled, double-blind study of intermittent therapy with itraconazole for the treatment of onychomycosis of the fingernail. J Am Acad Dermatol 1997; 36, 231 235. 83 Galimberti, R, Kowalczuk, A, Flores, V et al. Onychomycosis treated with a short course of oral terbinafine. Int J Dermatol 1996; 35, 374 375. 84 Albanese, G, Di Cintio, R, Martini, C, Nicoletti, A. Short therapy for tinea unguium with terbinafine: four different courses of treatment. Mycoses 1995; 38, 211 214. 85 Rakosi, T. & Terbinafine and onychomycosis (Abstract). %thinsp; Dermatologica 1990; 181, 174. 86 Shuster, S & Munro, C. Single dose treatment of fungal nail disease (letter). Lancet 1992; 339, 1066. 87 Zaias, N. Management of onychomycosis with oral terbinafine. J Am Acad Dermatol 1990; 23, 810 812. 88 Baudraz-Rosselet, F, Rakosi, T, Wili, PB et al. Treatment of onychomycosis with terbinafine. Br J Dermatol 1992; 126, 40 46. 89 Goodfield, MJD, Rowell, NR, Forster, RA et al. Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86–327, Lamisil), an orally active fungicidal agent. Br J Dermatol 1989; 121, 753 757. 90 Goodfield, MJD. Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatol 1992; 126, 33 35. 91 Goodfield, MJD. Clinical results with terbinafine in onychomycosis. J Dermatol Treat 1990; 1, 55 57. 92 Zaias, N & Serrano, L. The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine. Clin Exp Dermatol 1989; 14, 120 123. 93 Savin, RC & Atton, AV. Terbinafine in onychomycosis: a mini study. Int J Dermatol 1993; 32, 918 919. 94 Eastcott, DF. & Terbinafine and onychomcyosis (letter). N Z Med J 1991; 104, 17. 95 Wong, CK & Cho, YL. Very short duration therapy with oral terbinafine for fingernail onychomycosis. Br J Dermatol 1995; 133, 329 347. 96 Nolting, S, Bräutigam, M, Weidinger, G. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 1994; 130, 16 21. 97 Segal, R, Kritzman, A, Cividalli, L et al. Treatment of Candida nail infections with terbinafine. J Am Acad; Dermatol 1996; 35, 958 961. 98 Roberts, DT, Richardson, MD, Dwyer, PK et al. Terbinafine in chronic paronychia and Candida onychomycosis. J Dermatol Treat 1992; 3, 39 42. 99 Tosti, A, Piraccini, BM, Stinchi, C et al. Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals. Br J Dermatol 1996; 135, 799 802. 100 Lee, KH, Kim, YS, Kim, MS et al. Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients. Transplant Proc 1996; 28, 1488 1489. 101 Velthuis, PJ & Nijenhuis, M. Treatment of onychomycosis with terbinafine in patients with Down’s syndrome. Br J Dermatol 1995; 133, 144 145. 102 Török, I, Simon, G, Dobozy, A et al. Long-term post-treatment follow-up of onychomycosis treated with terbinafine: a multicentre trial. Mycoses 1998; 41, 63 65. 103 Wong, C-K & Cho, Y-L. Very short duration therapy with oral terbinafine for fingernail onychomycosis. Br J Dermatol 1995; 133, 329 331. 104 Shuster, S & Munro, CS. Single dose treatment of fungal nail disease. Lancet 1992; 339, 1066. 105 Nandwani, R, Parnell, A, Youle, M et al. Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis. Br J Dermatol 1996; 134, 110. 106 Herranz, P & De García Lucas, R et al. Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine. Br J Dermatol 1997; 137, 577 580. 107 Kuokkanen, K & Alava, S. Fluconazole in the treatment of onychomycosis caused by dermatophytes. J Dermatol Treat 1992; 3, 115 117. 108 Drake, L, Rich, P, Scher, RK et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail. J Am Acad Dermatol 1998; 38, S87 S94. 109 Ling, MR, Swinyer, LJ, Jarratt, MT et al. Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998; 38, S95 S102. 110 Rich, P, Scher, RK, Breneman, D et al. Pharmacokinetics of three doses of once-weekly fluconazole (1250, 300, and 450 mg) in distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998; 38, S103 S109. 111 Savin, RC, Drake, L, Babel, D et al. Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail. J Am Acad Dermatol 1998; 38, S110 S116. 112 Gupta, AK, Scher, RK, Rich, P. Fluconazole for the treatment of onychomycosis: an update. Int J Dermatol 1998; 37, 815 820. 113 Assaf, RR & Elewski, BE. Intermittent fluconazole dosing in patients with onychomycosis: Results of a pilot study. J Am Acad Dermatol 1996; 35, 216 219. 114 Aihara, Y, Mori, M, Yokota, S. Successful treatment of onychomycosis with fluconazole in two patients with hyperimmunoglobulin E syndrome. Pediat Dermatol 1996; 13, 493 495. 115 Smith, SW, Sealy, DP, Schneider, E, Lackland, D. An evaluation of the safety and efficacy at fluconazole in the treatment of onychomycosis. South Med J 1995; 88, 1217 1220. 116 Coldiron, B. Recalcitrant onychomycosis of the toenails successfully treated with fluconazole. Arch Dermatol 1992; 28, 909 910. 117 Nahass, GT & Sisto, M. Onychomycosis: successful treatment with once-weekly fluconazole. Dermatology 1993; 186, 59 61. 118 Hochman, LG, Scher, RK, Meyerson, MS et al. The safety and efficacy of oral fluconazole in the treatment of onychomycosis. J Geriat Dermatol 1993; 1, 169 172. 119 DerSimonian, R & Laird, NM. Meta-analysis in clinical trials. Control Clin Trials 1986; 7, 177 178. 120 Velanovich, V. Meta-analysis for combining Bayesian probabilities. Med Hypotheses 1 1991; 35, 192 195. 121 Villars, VV & Jones, TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol 1992; 126 (Suppl. 39), 61 69. 122 De Doncker, P, Gupta, AK, Marynissen, G et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 1997; 37, 969 974. 123 Price Probe, Version61 November, 15 . Data Update. San Bruno, Califormia: First Data Bank, 1998. 124 Annual Medicare Physician Fee Schedule-Carrier File. Baltimore. Health Care Finance Administration, 1995. 125 Clinical Diagnostic Lab Fee Schedule-Carrier File. Baltimore. Health Care Finance Administration, 1995. 126 Marchetti, A, Piech, CT, McGhan, WF et al. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther 1996; 18, 757 777. 127 Halpern, MT & Palmer, C. Modeling the cost-effectiveness of oral therapy for nail fungus. Am J Man Care 1996; 2, 59 66. 128 Angello, JT, Voytovich, RM, January, SA. A cost/efficacy analysis of oral antifungals indicated for the treatment of onychomycosis: griseofulvin, itraconazole, and terbinafine. Am J Man Care 1997; 3, 443 450. 129 Arikian, SR, Einarson, TR, Kobelt-Nguyen, G et al. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. Br J Dermatol 1994; 130, 35 44. 130 Einarson, TR, Arikian, SR, Shear, NH. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994; 130, 32 34. 131 Van Doorslaer, EKA, Tormans, G, Gupta, AK et al. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. Dermatology 1996; 193, 239 244. 132 Bootman, JL. Cost-effectiveness of two new treatments for onychomycosis: an analysis of two comparative clinical trials. J Am Acad Dermatol 1998; 38, S69 S72. 133 Kam, KM, Au, WF, Wong, PY, Cheung, MM. Onychomycosis in Hong Kong. Int J Dermatol 1997; 37, 757 761. 134 Rigopoulos, D, Katsiboulas, V, Koumantaki, E et al. Epidemiol Onychomycosis Southern Greece. Int J Dermatol 1998; 37, 925 928. 135 Burke, WA. Use of itraconazole in a patient with chronic mucocutaneous candidiasis. J Am Acad Dermatol 1989; 21, 1309 1310. 136 Hay, RJ & Clayton, YM. Fluconazole in the management of patients with chronic mucocutaneous candidosis. Br J Dermatol 1988; 119, 683 684. 137 Schatz, F, Bräutigam, M, Dobrowolski, E et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995; 20, 377 383. 138 De Doncker, P. Pharmacokinetics of oral antifungal agents. Dermatologic Ther 1997; 3, 46 57. 139 Gupta, AK, Sauder, DN, Shear, NH. Antifungal agents: an overview. Part II J Am Acad Dermatol 1994; 30, 911 933. 140 Gupta, AK, Scher, RK, De Doncker, P. Current management of onychomycosis. An overview. Dermatol Clin 1997; 15, 121 135. 141 Piérard, GE, Arrese, JE, Piérard-Franchimont, C. Treatment and prophylaxis of tinea infections. Drugs 1996; 52, 209 224. 142 Gupta, AK & Shear, NH. Terbinafine: an update. J Am Acad Dermatol 1997; 37, 979 988. 143 Shear, NH & Gupta, AK. Terbinafine for the treatment of pedal onychomycosis. Arch Dermatol 1995; 131, 937 942. 144 Gupta, AK, Katz, HI, Shear, NH. Drug interactions with itraconazole, fluconazole and terbinafine, and their management. J Am Acad Dermatol 1999; 41, 237 249. 145 De Doncker, P, Gupta, AK, Del Rosso, JQ et al. Safety of itraconazole pulse therapy in treatment of onychomycosis. An update. Postgrad Med. : (, 1999, Suppl.), 17 25. Citing Literature Volume38, IssueS2September 1999Pages 53-64 ReferencesRelatedInformation